{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:28:16Z","timestamp":1762867696980,"version":"build-2065373602"},"reference-count":87,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.endien.2022.11.011","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T09:25:18Z","timestamp":1668590718000},"page":"614-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas"],"prefix":"10.1016","volume":"69","author":[{"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eider","family":"Pascual-Corrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mart\u00ednez Lorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2022.11.011_bib0005","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0010","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol."},{"key":"10.1016\/j.endien.2022.11.011_bib0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.endien.2022.11.011_bib0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40292-020-00415-9","article-title":"Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension","volume":"27","author":"Rossi","year":"2020","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"10.1016\/j.endien.2022.11.011_bib0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.endinu.2020.03.002","article-title":"Practical guide on the initial evaluation, follow-up, treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology, Nutrition","volume":"67","author":"Araujo-Castro","year":"2020","journal-title":"Endocrinol Diabetes Nutr."},{"key":"10.1016\/j.endien.2022.11.011_bib0030","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0035","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens."},{"key":"10.1016\/j.endien.2022.11.011_bib0040","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s40618-021-01649-7","article-title":"Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approach","volume":"44","author":"Araujo-Castro","year":"2021","journal-title":"J Endocrinol Invest."},{"key":"10.1016\/j.endien.2022.11.011_bib0045","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0050","article-title":"Personalized management of pheochromocytoma and paraganglioma","author":"N\u00f6lting","year":"2021","journal-title":"Endocr Rev."},{"key":"10.1016\/j.endien.2022.11.011_bib0055","doi-asserted-by":"crossref","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Ta\u00efeb","year":"2019","journal-title":"Endocr Relat Cancer."},{"key":"10.1016\/j.endien.2022.11.011_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cen.14375","article-title":"PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era","volume":"95","author":"Ryder","year":"2021","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.endien.2022.11.011_bib0065","first-page":"685","article-title":"[(123)I]metaiodobenzylguanidineand[(111)In]octreotide uptake in benign and malignant Pheo-chromocytomas","volume":"86","author":"van der Harst","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2796.2004.01425.x","article-title":"Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour","volume":"257","author":"Pacak","year":"2005","journal-title":"J Intern Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0080","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1200\/JCO.2010.31.7131","article-title":"Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas","volume":"29","author":"Cecchin","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.endien.2022.11.011_bib0085","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0090","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.24796","article-title":"177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy","volume":"116","author":"Garkavij","year":"2010","journal-title":"Cancer."},{"key":"10.1016\/j.endien.2022.11.011_bib0095","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res."},{"key":"10.1016\/j.endien.2022.11.011_bib0105","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00259-010-1545-7","article-title":"131I\/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging","volume":"37","author":"Bombardieri","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"Fonte","year":"2012","journal-title":"Endocr Relat Cancer."},{"key":"10.1016\/j.endien.2022.11.011_bib0115","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1210\/jc.2009-1054","article-title":"6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess","volume":"94","author":"Fiebrich","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0120","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1210\/jc.2019-00018","article-title":"The role of 68Ga-DOTA-Octreotate PET\/CT in follow-up of SDH-associated pheochromocytoma and paraganglioma","volume":"104","author":"Kong","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0125","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","author":"Srirajaskanthan","year":"2010","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0130","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.endien.2022.11.011_bib0135","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2967\/jnumed.120.259697","article-title":"Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.625312","article-title":"Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: old players in a new precision medicine world","volume":"12","author":"Patel","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.endien.2022.11.011_bib0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/ERC-10-0175","article-title":"Expression of somatostatin receptors, dopamine D 2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas","volume":"18","author":"Saveanu","year":"2011","journal-title":"Endocr Relat Cancer."},{"key":"10.1016\/j.endien.2022.11.011_bib0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA\u2013conjugated somatostatin receptor\u2013targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.endien.2022.11.011_bib0160","first-page":"145","article-title":"SPECT\/TC con an\u00e1logos de la somatostatina en el diagn\u00f3stico de los tumores neuroendocrinos","volume":"50","author":"Sainz Esteban","year":"2013","journal-title":"An Real Acad Med Cir Vall."},{"key":"10.1016\/j.endien.2022.11.011_bib0165","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jcem.86.2.7194","article-title":"Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors","volume":"86","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0170","first-page":"145","article-title":"Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors","volume":"39","author":"Lastoria","year":"1995","journal-title":"Q J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0175","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","article-title":"Imaging of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0180","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","article-title":"Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0185","first-page":"E176","article-title":"Functional imaging experience in a germline fumarate hydratase mutation\u2013positive patient with pheochromocytoma and paraganglioma","volume":"2","author":"Nambuba","year":"2016","journal-title":"AACE Clin Case Rep."},{"key":"10.1016\/j.endien.2022.11.011_bib0190","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos sanitarios. Ficha t\u00e9cnica Dopacis. 2017 [accessed 1 Jun 2021]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/p\/73797\/Prospecto_73797.html."},{"key":"10.1016\/j.endien.2022.11.011_bib0195","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet."},{"key":"10.1016\/j.endien.2022.11.011_bib0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.108.060731","article-title":"18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?","volume":"50","author":"Ta\u00efeb","year":"2009","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0205","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.endien.2022.11.011_bib0210","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.sult.2019.07.002","article-title":"PET\/MRI vs PET\/CT in head and neck imaging: when, why, and how?","volume":"40","author":"Ryan","year":"2019","journal-title":"Semin Ultrasound CT MR."},{"key":"10.1016\/j.endien.2022.11.011_bib0215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.clinimag.2021.07.028","article-title":"[68Ga]-DOTATATE PET\/MRI in the diagnosis and management of recurrent head and neck paraganglioma with spinal metastasis","volume":"79","author":"Kim","year":"2021","journal-title":"Clin Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0220","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.115.156539","article-title":"64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients","volume":"56","author":"Pfeifer","year":"2015","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0230","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.119.236091","article-title":"64Cu-DOTATATE PET\/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial","volume":"61","author":"Delpassand","year":"2020","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0235","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-PronO study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0240","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MED.0000000000000544","article-title":"High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease","volume":"27","author":"Jimenez","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"10.1016\/j.endien.2022.11.011_bib0245","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0250","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/RLU.0000000000001674","article-title":"Comparison of the 68Ga-DOTATATA PET\/CT, FDG PET\/CT, and MIBG SPECT\/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas","volume":"42","author":"Jing","year":"2017","journal-title":"Clin Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0255","first-page":"419","article-title":"Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging","volume":"52","author":"Havekes","year":"2008","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0260","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0265","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.endien.2022.11.011_bib0270","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","author":"Janssen","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0275","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0280","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fendo.2018.00515","article-title":"Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging","volume":"9","author":"Alrezk","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.endien.2022.11.011_bib0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol."},{"key":"10.1016\/j.endien.2022.11.011_bib0290","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet."},{"key":"10.1016\/j.endien.2022.11.011_bib0295","first-page":"e89","article-title":"Dopamine-secreting phaeochromo-cytomas and paragangliomas: clinical features and management","volume":"51","author":"Foo","year":"2010","journal-title":"Singapore Med J."},{"key":"10.1016\/j.endien.2022.11.011_bib0300","first-page":"1154","article-title":"Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion","volume":"100","author":"Proye","year":"1986","journal-title":"Surgery."},{"key":"10.1016\/j.endien.2022.11.011_bib0305","first-page":"5153","article-title":"Dopamine excess in patients with head and neck paragangliomas","volume":"30","author":"Van Der Horst-Schrivers","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.endien.2022.11.011_bib0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1196\/annals.1353.050","article-title":"Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)","volume":"1073","author":"Fitzgerald","year":"2006","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.endien.2022.11.011_bib0315","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/qjmed\/hcu208","article-title":"Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre","volume":"108","author":"Rutherford","year":"2015","journal-title":"QJM."},{"key":"10.1016\/j.endien.2022.11.011_bib0320","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest."},{"key":"10.1016\/j.endien.2022.11.011_bib0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131i-meta-iodobenzylguanidine (131I-mIBG)","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.endien.2022.11.011_bib0330","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF03345807","article-title":"Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases","volume":"15","author":"Schlumberger","year":"1992","journal-title":"J Endocrinol Invest."},{"key":"10.1016\/j.endien.2022.11.011_bib0335","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose 131I-Metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer."},{"key":"10.1016\/j.endien.2022.11.011_bib0340","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0345","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0350","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/MNM.0b013e32834bad97","article-title":"[131I]Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies","volume":"32","author":"Rachh","year":"2011","journal-title":"Nucl Med Commun."},{"key":"10.1016\/j.endien.2022.11.011_bib0355","first-page":"79","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol Cancer Clin Trials."},{"key":"10.1016\/j.endien.2022.11.011_bib0360","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clon.2011.12.003","article-title":"Radionuclide therapy in neuroendocrine tumours: a systematic review","volume":"24","author":"Gulenchyn","year":"2012","journal-title":"Clin Oncol."},{"key":"10.1016\/j.endien.2022.11.011_bib0365","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequelae and survivorship in patients treated with 131I-MIBG therapy","volume":"109","author":"Sze","year":"2013","journal-title":"Br J Cancer."},{"key":"10.1016\/j.endien.2022.11.011_bib0370","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131i]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.endien.2022.11.011_bib0375","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The north american neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas."},{"key":"10.1016\/j.endien.2022.11.011_bib0380","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.semnuclmed.2006.03.007","article-title":"Imaging of neuroendocrine tumors","volume":"36","author":"Rufini","year":"2006","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0385","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000074662","article-title":"Somatostatin receptors in pheochromocytoma","volume":"31","author":"De Herder","year":"2004","journal-title":"Front Horm Res."},{"key":"10.1016\/j.endien.2022.11.011_bib0390","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1210\/jc.2003-030262","article-title":"Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy","volume":"88","author":"Mundschenk","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0395","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.endien.2022.11.011_bib0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1536-1632(03)00038-6","article-title":"Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors","volume":"5","author":"Kowalski","year":"2003","journal-title":"Mol Imaging Biol."},{"key":"10.1016\/j.endien.2022.11.011_bib0405","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.mnm.0000189780.54658.e8","article-title":"Discordant localization of 2-[f]-fluoro-2-deoxy-d-glucose in 6-[f]-fluorodopamine- and [i]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites","volume":"27","author":"Mamede","year":"2006","journal-title":"Nucl Med Commun."},{"key":"10.1016\/j.endien.2022.11.011_bib0410","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.endien.2022.11.011_bib0415","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1530\/EC-20-0292","article-title":"177Lu-dotatate therapy in metastatic\/inoperable pheochromocytoma-paraganglioma","volume":"9","author":"Jaiswal","year":"2020","journal-title":"Endocr Connect."},{"key":"10.1016\/j.endien.2022.11.011_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","author":"Severi","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.endien.2022.11.011_bib0425","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","author":"Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.endien.2022.11.011_bib0430","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/qjmed\/hcu208","article-title":"Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre","volume":"108","author":"Rutherford","year":"2015","journal-title":"QJM An Int J Med."},{"key":"10.1016\/j.endien.2022.11.011_bib0435","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"Van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)."}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253001802200169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253001802200169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:28Z","timestamp":1762866988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S253001802200169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S253001802200169X"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2022.11.011","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2022.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2021.09.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}